R&D channel feed

An­oth­er failed tri­al for Or­p­hazyme's 'pipeline-in-a-pro­duc­t' leaves shad­ow on drug's fu­ture

5 years ago

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

5 years ago
Pharma

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

5 years ago

With no up­front pay­ment or mile­stones on the line, Nkar­ta and CRISPR join forces on CAR-NK search

5 years ago
Deals

Tak­ing dou­ble Covid-19 hits, Mer­ck writes off $170M for scrapped drug, high­lights $600M in missed sales

5 years ago

Mod­er­na says Covid-19 vac­cine boost­er in­creased im­mune re­sponse against vari­ants of con­cern

5 years ago
Coronavirus

Ada­gio of­fers first peek at Covid-19 an­ti­body da­ta, with pre­ven­ta­tive num­bers that may ri­val mR­NA vac­cines

5 years ago
Coronavirus

Re­searchers are look­ing to solve PTSD. Could MD­MA-as­sist­ed ther­a­pies pro­vide an an­swer?

5 years ago

How much? Pfiz­er ex­pects to reap at least $26B from Covid vac­cine in 2021

5 years ago
Coronavirus

Pfiz­er hits the brakes on their piv­otal tri­al for a BC­MA/CD3 bis­pe­cif­ic on safe­ty con­cerns while FDA road­block is hold­ing up Duchenne MD PhI­II

5 years ago

Al­ny­lam pro­vides long-term look at Oxlu­mo, aim­ing to fur­ther carve out stake in PH1 mar­ket

5 years ago

ICH plots ma­jor over­haul of good clin­i­cal prac­tice guide­line

5 years ago
FDA+

Did Sarep­ta re­al­ly score a suc­cess in the lat­est cut of their next-gen Duchenne MD drug? As usu­al, that's a lit­tle com­pli­cat­ed

5 years ago

Mer­ck, Roche and Bris­tol My­ers nab 4 of 6 pos­i­tive ODAC votes for ‘dan­gling’ ac­cel­er­at­ed ap­provals

5 years ago
Pharma
FDA+

AskBio bails on in-li­censed gene ther­a­py pro­gram af­ter find­ing is­sues with 3rd-par­ty man­u­fac­tur­er

5 years ago
Manufacturing

Cara touts sub­group in failed atopic der­mati­tis tri­al, but stock craters

5 years ago

Tril­li­um is hunt­ing gi­ants with its an­ti-CD47 drug, but ques­tions over a high-dose so­lo reg­i­men still linger

5 years ago

What caused Roche's Hunt­ing­ton's drug tomin­ersen to hit the skids in late-stage test? It's com­pli­cat­ed, an­a­lysts say

5 years ago

Tech glitch­es over­shad­ow FDA on­col­o­gy ad­comm as a sol­id ma­jor­i­ty of ad­vis­ers vote to keep Roche's Tecen­triq in mTNBC

5 years ago
FDA+

Watch out Clar­itin: Aldeyra an­nounces clean sweep in PhI­II for new al­ler­gy drug

5 years ago

Eli Lil­ly aban­dons its plans to pitch its block­buster con­tender mirik­izum­ab for pso­ri­a­sis af­ter siz­ing up heavy­weight ri­vals

5 years ago

Loxo founder Josh Bilenker, No­var­tis on­col­o­gy leader Jeff En­gel­man join forces to de­but can­cer R&D play­er

5 years ago
Startups

As­traZeneca and Sanofi tout break­through in €645M al­liance against lead­ing cause of in­fant death

5 years ago

Bris­tol My­er­s' next-gen im­munol­o­gy med busts Am­gen's Ote­zla in head-to-head study. Is a show­down com­ing?

5 years ago
First page Previous page 171172173174175176177 Next page Last page
A service from the Financial Times